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Abstract: The management of metastatic urothelial carcinoma (UC) of the bladder is a common 
and complex clinical challenge. Despite the fact that UC is one of the most frequent tumors 
in the population, long term survival for metastatic disease remains low, and chemotherapy 
is curative for only a small minority of patients. UC is genetically heterogeneous, and it is 
surrounded by a complex tissue microenvironment. The problems of clinical practice in the 
ﬁ  eld of metastatic bladder cancer have begun to stimulate translational research. Advances in 
the understanding of the molecular biology of urothelial cancer continue to contribute to the 
identiﬁ  cation of molecular pathways upon which new therapeutic approaches can be targeted. 
New agents and strategies have recently been developed which can direct the most appropri-
ate choice of treatment for advanced disease. A review of literature published on the targeted 
therapy for metastatic bladder cancer is presented, focusing on the molecular pathways shut 
down by the new therapeutic agents.
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Introduction
The design and development of agents that act on speciﬁ  c molecular and cellular targets 
are considered as a rational approach to control cancer. This strategy for control of 
cancer is based on the presumption that because cancer develops through a multi-step 
process, each step may be a prospective target for reversing or suppressing the process. 
There are a number of limitations on drug targeting technology, but, at present, the 
more difﬁ  cult limitations are imposed by tumors themselves and by the host’s response 
to a tumor. Moreover, successes in vitro are disputable without corresponding data in 
the more composite organism level.
Bladder cancer is one of the most common cancers, being the 4th most common 
malignancy in men and the 13th most common malignant cancer in women in the 
United States (Jemal et al 2007). In 2007, it is estimated that 67,160 new cases of 
bladder cancer will be diagnosed, and 13,750 deaths will be attributed to this disease 
(Jemal et al 2007). The incidence is higher in males (with a ratio of 3:1) and in the 
elderly (Jemal et al 2007). Urothelial carcinoma (UC) (previously designated as tran-
sitional carcinoma or TCC) accounts for approximately 95% of bladder malignancies 
(Baffa et al 2006).
Despite undergoing surgery with curative intent, a large proportion of patients with 
UC will develop metastatic disease while others will have metastases at the time of 
initial presentation (Calabro and Sternberg 2006). Accurate clinical staging of blad-
der cancer remains difﬁ  cult and inaccurate, with pathologic upstaging after radical 
cystectomy commonly demonstrated for clinically localized tumors (Ficarra et al 
2005). Recent studies have demonstrated that combination therapy with neoadjuvant 
chemotherapy followed by radical surgery for muscle-invasive diseases offers a small 
but deﬁ  nite survival advantage (Grossman et al 2003; Vale 2005). Once metastatic, Biologics: Targets & Therapy 2007:1(4) 394
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however, the relative 5-years survival rate is 6%, whereas 
the overall 5-years survival for all stages is 82% (Mitra et al 
2006). For patients with muscle-invasive disease, the most 
common pattern of metastasis is to regional lymph nodes, 
but distant spread to lungs, liver, skin and bone is also typi-
cal (Raghavan et al 1990). Metastases to abdominal viscera, 
brain, and meninges are seen less frequently.
Sites of metastatic involvement correlate with response 
rate and survival and are important predictors of treatment 
outcome (Parimoo and Raghavan 2000). Patients with lymph 
node, lung, and soft-tissue metastases have better survival 
than those with metastases to bone and liver (Geller et al 
1991; Loehrer et al 1992). Biopsies of distant metastatic sites 
are often consistent histologically with UC pattern. However, 
a signiﬁ  cant disparity within these metastatic lesions with 
respect to growth parameters, ploidy, karyotype, oncogene 
expression, tumor markers, grade, and histologic features has 
been demonstrated (Raghavan et al 1990; Geller et al 1991; 
Loehrer et al 1992).
Patients with metastatic UC are usually treated with sys-
temic chemotherapy (Sternberg et al 1989; Geller et al 1991; 
Pagano et al 1991; Calabro and Sternberg 2006). For more 
than two decades, the standard treatment has been combina-
tion therapy with methotrexate, vinblastine, adriamycin and 
cisplatin (MVAC). This regimen is consistently reported to 
produce a median survival in the range of 13–15 months 
(Sternberg et al 1989; Calabro and Sternberg 2006). MVAC 
has signiﬁ  cant toxicity, however, primarily neutropenia, 
neutropenic fever and severe mucositis, which limits its 
use in the predominantly older bladder cancer population. 
Combination therapy with gemcitabine and cisplatin (GC) 
has shown similar efﬁ  cacy as MVAC, with less toxicity 
and a much lower toxic death rate (1% vs 3% for MVAC), 
leading to widespread substitution of GC for MVAC in 
clinical practice (von der Maase et al 2000). In the search 
for regimens more active than MVAC, regimens based on 
gemcitabine, ifosfamide, and/or paclitaxel have attracted 
considerable interest (Roth et al 1994; Bajorin et al 1998; 
Redman et al 1998; Vaughn et al 1998), but until now no 
substantial improvement in survival has been observed. Most 
of these treatments are based on the pathologic staging of 
tumors and do not take molecular proﬁ  les into consideration. 
These facts highlight the limited effectiveness of the current 
therapeutic regimens and that novel treatment strategies are 
urgently required. Novel targeted therapies hold promise to 
improve the current results of metastatic bladder cancer treat-
ment. Several trials are ongoing evaluating these new agents 
alone or in combination with chemotherapy. The integration 
of these newer biologic agents should be a primary direction 
of research with the objective to interfere with multiple 
aspects of bladder cancer progression.
Molecular events in metastatic 
bladder cancer
The identification of mutated genes and gene products 
which are aberrantly expressed in invasive and metastatic 
bladder tumors permits the design of molecularly targeted 
therapies. There have been recent major developments in our 
understanding of the molecular phenotype of bladder cancers 
(Table 1) (Dimopoulos and Moulopoulos 1998; Knowles 
2001; Cote and Datar 2003; Baffa et al 2006; Abraham et al 
2007). Over the last two decades, scientists have demon-
strated that two distinct molecular pathways are involved 
in the genesis of UC based on histopathology and clinical 
behavior (Figure 1) (Wu 2005; Baffa et al 2006): superﬁ  cial 
papillary and invasive non-papillary bladder tumors.
Papillary carcinoma, which account for more than 80% 
of bladder tumors, has a tendency to recur locally (approxi-
mately 70%), but rarely invades and metastasizes. On the 
other hand, most invasive bladder tumors have no known 
papillary precursor, are solid invasive lesions, are commonly 
associated with carcinoma in situ (CIS) and have a much 
less favorable prognosis. Genetic analyses have shown that 
CIS exhibits a spectrum of genetic alterations (such as TP53 
mutation and loss of heterozygosity -LOH- at 3p, 8p, 13q, 
and 17p) similar to that seen in invasive UC and very distinct 
from that seen in low grade papillary UC, where only LOH 
at chromosome 9 is common (Wu 2005).
In invasive and metastatic bladder cancers, among the 
different oncogenes and tumor suppressor genes (TSG) 
which have been studied (Table 1), particular interest has 
been focused on defects in pathways controlling the G1/S 
cell cycle checkpoint (involving the tumor suppressor genes 
TP53 and RB1), angiogenesis, DNA methylation, multidrugs 
resistant genes and on activation of the Ras-MAPK signal 
transduction pathway, in which associations between molecu-
lar abnormalities and tumor prognosis have been identiﬁ  ed 
(Knowles 2001).
Cell cycle regulators
A prerequisite for normal cell proliferation is an orderly 
progression through the cell cycle, which is predominately 
controlled by protein complexes that are composed of cyclins 
and cyclin-dependent kinases (CDK). These complexes con-
trol progression through the cell cycle by phosphorylating 
key proteins that are involved in cell cycle transition points. Biologics: Targets & Therapy 2007:1(4) 395
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The fundamental and best studied genes involved in cell 
cycle regulation are the tumor suppressor genes RB1, TP53, 
CDKN2A (P16/INK4A-ARF) and CDKN1A (P21WAF1/
Cip1) and the oncogene MDM2.
The p53 protein is a central molecule in several important 
cellular programs related to cancer development, progres-
sion and response to therapy, as apoptosis and DNA repair 
(Cote et al 1997). It inhibits cell cycle progression at G1-S 
transition and mediates its control through the transcriptional 
activation of CDKN1A. TP53 mutations are the most common 
genetic defect in human tumors (Hollstein et al 1991) and 
most studies on TP53 have used immunohistochemical detec-
tion of the p53 protein as a surrogate for gene inactivation by 
mutation. Mutant p53 has an increased half life and can be 
easily detected, whereas normal physiological concentrations 
of the wild-type protein are undetectable. The mutations are 
generally missense point mutations, which result in altered 
proteins that are resistant to normal regulatory degradation 
by the ubiquitin pathway (Dowell 1995). In bladder cancer, 
mutation of p53 is a feature of more advanced, poorly dif-
ferentiated tumors and appears to be associated with a high 
risk of metastatic recurrence and a poor prognosis (Esrig et al 
1993; Lipponen 1993; Sarkis et al 1993, 1995; Soini et al 
1993; Esrig et al 1994; Pﬁ  ster, Flaman et al 1999; Pﬁ  ster, 
Moore et al 1999). TP53 has been evaluated in bladder can-
cer in order to predict and to be correlated with an increased 
chemosensitivity (McKnight et al 2005; Stein, Grossfeld 
et al 1998). Adjuvant chemotherapy was associated with a 
decreased risk of recurrence and improvement in survival 
when given to patients with TP53-altered tumors (Cote et al 
1997). In a transfected bladder cell line, the re-expression 
of a wild-type p53 protein suppressed the cytotoxic effects 
of paclitaxel and gemcitabine (Kielb et al 2001). Paclitaxel 
was shown to require functionally mutated TP53 to induce 
cell death, indicating that it may be more effective against 
UC with TP53 mutations, while gemcitabine was effective 
regardless of p53 protein function. Induction of TP53 gene 
expression has been shown to be facilitated by prior expo-
sure to cytotoxic agents such as cisplatin and mitomycin C 
(Parimoo and Raghavan 2000). This altered expression of 
TP53 may correlate with increased resistance to combina-
tion chemotherapy protocols (ie, MVAC) (Cote et al 1997; 
Sarkis et al 1995) and may be associated with previous intra-
vesicular treatment (Bajorin et al 1998). All these ﬁ  ndings 
may provide a rationale for selecting chemotherapy on the 
basis of the TP53 status.
However, not all bladder tumors with TP53 alterations 
progress or recur (Esrig et al 1993; Esuvaranathan et al 2007). 
As previously described, the action of wild type TP53 on cell 
cycle regulation is mediated, in part, through up-regulation of 
CDKN1A (P21/WAF1). p21 protein, a CDK inhibitor, binds 
and inhibits cdk2, a protein that is necessary for transition 
into the next phase of the cell cycle. Alterations of TP53 
result in loss of p21 expression, which leads to unregulated 
PAPILLARY
LOW GRADE
PAPILLARY
HIGH GRADE
NORMAL
UROTHELIUM
CARCINOMA IN
SITU
METASTASIS T1 T2-T4
RECURRENT
DISEASE
9q-, 9p-
P53, 3p-, 8p-, 13q-,
17p-
ERBB-2, 8p-, 11p-
H-RAS, EGFR,
CCDN1
9q-, 9p-, 13q (RB), 17q
(ERBB-2)
P53, P21 P53, P16, 13q- (RB), 17q (ERBB-
2), 8p- (FEZ1/LZTS1), 3p- (FHIT),
7q (EGFR), 11p-, 20q-
Figure 1 Proposed model for urothelial tumorigenesis and progression. Papillary tumors and carcinoma in situ (CIS) have unique molecular proﬁ  les and arise from two 
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cell growth. However, it has been shown that p21 expression 
can also be regulated through p53-independent pathways 
which may maintain p21 expression despite the presence of 
altered p53 (Kinoshita et al 1997). Thus, from a theoretical 
point of view, p21 protein detection should provide additional 
information to p53 positivity alone. In bladder cancer, the 
loss of p21 expression can be a signiﬁ  cant and independent 
predictor of UC progression, whereas the maintenance of 
p21 expression appears to abrogate the deleterious effects 
of TP53 alterations (Stein, Ginsberg et al 1998). In multi-
variate analysis, p21 labeling was an independent predictor 
of tumor recurrence and of survival (Stein, Grossfeld et al 
1998). Patients with TP53-altered/p21-negative tumors 
demonstrated a higher rate of recurrence and worse survival 
compared with those with TP53-altered/p21-positive tumors 
(Migaldi et al 2000; Stein, Ginsberg et al 1998).
MDM2 is another gene correlated with TP53 expression. 
In normal cells, MDM2 regulates TP53 function by marking 
p53 protein for degradation via ubiquitin conjugation and 
inactivating p53 by binding to its transactivation domain 
(Oliner et al 1992; Wu et al 1993). Increased p53 levels 
transactivate the MDM2 promoter causing its upregulation. 
Ampliﬁ  cation of MDM2 results in the escape from TP53-
regulated growth control. Nevertheless, the role of MDM2 
in regulating p53 protein levels in UC remains unclear. 
It is generally agreed that Mdm2 over-expression itself 
provides no independent prognostic information over 
clinico-pathological parameters (Schmitz-Drager et al 
1997; Shiina et al 1999; Uchida et al 2002). However, the 
combination of MDM2 and TP53 status could determine a 
higher prognostic power on progression (Schmitz-Drager 
et al 1997; Shiina et al 1999) and survival (Shiina et al 1999) 
in bladder cancer patients.
The RB1 gene was the ﬁ  rst tumor suppressor gene identi-
ﬁ  ed (Friend et al 1986). In its physiologic active form the 
nuclear phosphoprotein Rb1 encoded protein inhibits cell 
cycle progression at the G1 to S checkpoint by binding to a 
number of cellular proteins including the transcription factor 
E2F (Chellappan et al 1991). The inactivation of RB1 has 
been described as an important step in carcinogenesis and 
progression of various tumors (Bagchi et al 1991; Goodrich 
2006). The comparison of immunohistochemical Rb1 expres-
sion and molecular analysis in primary UCs showed that 
RB1 alterations (observed in the 19%–29.4% of the tumors) 
are more frequently seen in muscle-invasive and high-grade 
tumors (Cordon-Cardo et al 1992; Cordon-Cardo et al 1997; 
Xu et al 1993), and that in patients with muscle-invasive 
bladder cancer the 5-year survival was signiﬁ  cantly decreased 
in cases with altered Rb1 protein (Cordon-Cardo et al 1992; 
Logothetis et al 1992; Gallucci et al 2005).
Important in the regulation of the cell cycle is also 
the CDKN2A gene (also known as P16, INK4A, MTS1, 
CDKN2A), which is a well-characterized CDK inhibitor 
(Lo et al 1996). This protein functions upstream of Rb1 
to block cyclin-D directed phosphorylation of Rb1, thus 
inducing G1 arrest. CDKN2A mutations and homozygous 
deletions have been detected in the 3.1% and 14.1% of 
bladder cancers analyzed, respectively (Orlow et al 1999). 
Furthermore, CDKN2A is thought to be susceptible to 
transcriptional silencing by promoter methylation, which 
affects from 14.9% to 26.5% of the tumors tested (Orlow 
et al 1999; Chan et al 2002). Inactivation of CDKN2A by 
any of the mechanisms will lead to affect both p16 and 
p19ARF proteins, and subsequently disrupting the Rb1 and 
p53 pathways (Orlow et al 1999).
The interaction of p53 and p21 proteins in cell cycle 
regulation, and the data looking at the cooperative effects 
of p53 and Rb1 (Cordon-Cardo et al 1997), provide good 
examples of the increasing evidence that mutation in a single 
TSG is unlikely to be the only factor resulting in carcinogen-
esis. Several studies have conducted multivariate analyses 
using various combinations of cell cycle regulators mark-
ers (TP53, CDKN1A, RB1, CDKN2A, MDM2) to generate 
prognostic panels (Lu et al 2002; Shariat et al 2003; Shariat 
et al 2004). Lu et al (2002) and Shariat et al (2003) found 
that the 12.1% of the 140 tumor analyzed, had an altered p53 
pathway, deﬁ  ned by the detection of mutant TP53 and/or p53 
nuclear overexpression, loss of p21 nuclear expression, and 
Mdm2 nuclear overexpression. Moreover, they exhibited 
the worst clinical outcome in the observation period. Shariat 
et al (Shariat et al 2004), found that the 83% of 80 bladder 
cancers had at least one marker altered (p53, p21, and pRB 
or p16), and 21 patients (26%) had all three altered. These 
studies demonstrated a biological and pathological relation-
ship between these markers spanning multiple molecular 
pathways and progression, suggesting their important role 
in bladder carcinogenesis and their rational target for the 
design of molecularly targeted therapies.
Tumor angiogenesis
Angiogenesis is not only important in maintaining the supply 
of oxygen and nutrients to the proliferating tumor cells and 
to the metastatization of the primary tumor, but also for the 
survival and spreading of secondary localizations. The most 
important factor affecting this process is the pro-angiogenic 
vascular endothelial growth factor (VEGF). High serum Biologics: Targets & Therapy 2007:1(4) 398
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VEGF levels and VEGF IHC expression have been associated 
with high UC stage and grade, vascular invasion, CIS, metas-
tases and poor disease free survival (Bernardini et al 2001; Zu 
et al 2006). Moreover, VEGF levels affect the production of 
interleukin-8 (IL-8) and matrix metalloproteinases (MMPs) 
(Nutt et al 1998), which enhances angiogenesis of the tumor, 
and migration and invasion of bladder cancer cells. Increased 
expression of MMP-9, IL-8 and VEGF has been proven to 
be correlate with stage and outcome of advanced bladder 
tumors (Black and Dinney 2007).
DNA methylation
The promoter methylation has been demonstrated to be 
a frequent mechanism of inhibition for important genes 
including those that inﬂ  uence the cell cycle and signal trans-
duction in cancer (Chan et al 2002). In UC, the role of this 
epigenetic event in the silencing of TSGs is still under study. 
The promoter region of TP53 gene is almost never methyl-
ated in muscle-invasive UC (Kunze et al 2006), whereas, as 
mentioned above, CDKN2A is susceptible to transcriptional 
silencing by promoter methylation (Orlow et al 1999; Chan 
et al 2002). Recently, additional ﬁ  ndings are conﬁ  rming 
the importance of this mechanism in the process of bladder 
metastatization (Nixdorf et al 2004). Further studies should 
elucidate the signiﬁ  cance of hyper-methylation and the role 
of demethylating agents in the treatment of locally advanced 
and metastatic UCs (Cote and Datar 2003).
Multidrug resistant genes
The tumor resistance to chemotherapy is the major problem 
affecting the management of metastatic and aggressive blad-
der cancers. Over-expression of the MDR1 gene leads to drug 
resistance via up-regulation of a membrane-bound 190 kDa 
phosphoglycoprotein, that serves as an energy-dependent 
drug ﬂ  ux pump and eliminates toxic metabolites out of the 
cells (Hasegawa et al 1995). The expression of this protein 
correlated in various tumors with low local drug accumula-
tion and increased drug resistance (Endicott and Ling 1989), 
which has also been observed in bladder cancer (Clifford et al 
1994; Naito et al 1992; Petrylak et al 1994). Petrylak et al 
(1994), observed a positive p-glycoprotein immunostaining 
in 6 of 46 untreated primary lesions (13%), while 6 of 16 
(38%) post-therapy primary tumors were immunoreactive. 
None of the untreated metastases (0 of 17) were positive; 
however, 6 of 11 (55%) post-therapy specimens showed 
varied percentages of positivity. Of interest, the highest 
percentage, 50%–70% of tumor cells stained, was observed 
in metastatic lesions from patients who had received 6 or 
more chemotherapy cycles. These characteristics suggest 
that targeting of MDR1 expression may improve the response 
of advanced and metastatic bladder tumors to systemic 
chemotherapy.
Growth factor receptors
In invasive and metastatic UC two receptor tyrosine kinases, 
the epidermal growth factor receptor (EGFR) and ERBB-2 
(also called HER-2 or NEU), are over-expressed (35%–86% 
for EGFR, and 41%–52% for ERBB-2) and associated with 
poor outcome (Lipponen and Eskelinen 1994; Ravery et al 
1997; Kruger et al 2002; Hussain et al 2007)
Preclinical and clinical data strongly support the 
involvement of the EGFR in the growth and progression of 
human cancers (Nicholson et al 2001; Mendelsohn 2002; 
Dei Tos 2007) as well as demonstrate a high correlation in 
cancer patients between receptor/ligand expression and poor 
prognosis (Nicholson et al 2001). EGFR is a transmembrane 
glycoprotein that is activated by the binding of epidermal 
growth factor (EGF) and of transforming growth factor (TGF) 
to its external domain. In normal cells, binding of EGF causes 
activation of the EGFR, leading to receptor dimerization and 
autophosphorylation. The activated receptor then recruits 
proteins that convert Ras to its activated state, which can then 
transduce a mitogenic signal through the Ras-MAPK pathway 
by activating the MAPK/ERK complex. This activation sets 
off several cell regulation processes such as proliferation, 
migration and adhesion (Messing 1990; Messing 1992; 
Roberts and Der 2007). Although the mechanism by 
which EGFR regulates tumor biology in bladder cancer is 
not clearly deﬁ  ned, it has been demonstrated that EGFR 
signaling regulates cellular proliferation, differentiation, 
survival, invasion; and it is implicated in the induction of 
tumor induced angiogenesis and metastasis (Mendelsohn 
and Dinney 2001; Nicholson et al 2001).
Immunohistochemical studies have demonstrated that 
EGFR is over-expressed in human UC compared to the nor-
mal urothelium (Neal and Mellon 1992; Rotterud et al 2007). 
Moreover, it has been observed that normally the urothelial 
cells which over-express EGFR are found primarily in the 
basal layer of the urothelium (Messing 1990; Messing 1992; 
Rotterud et al 2007), whereas, in malignant and dysplastic 
urothelium, EGFR is expressed in all cell layers (Baffa et al 
2006). Most importantly, it has also been observed that the 
level of EGFR expression directly correlates with tumor 
grade, stage, and survival (Neal et al 1990; Messing 1992; 
Lipponen and Eskelinen 1994; Mellon et al 1995; Chow et al 
1997; Popov et al 2004). Patients with muscle-invasive UC Biologics: Targets & Therapy 2007:1(4) 399
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which over-express EGFR have only a 20% probability of 
long term cancer-speciﬁ  c survival, which is signiﬁ  cantly 
worse than the survival of those whose tumors did not express 
EGFR (Nguyen et al 1994). In metastatic bladder cancer, 
the majority of metastases from patients over-expresses the 
EGFR, and this expression is not down-regulated by chemo-
therapy or radiation (Nguyen et al 1994).
In normal and malignant cells, the preferred partner for 
the EGFR molecule is erbB-2, a member of the ERBB gene 
family, and encoded by the ERBB-2/HER-2/NEU gene. This 
heterodimeric formation acts as the most efﬁ  cient receptor 
for EGF. As observed in breast, gastric and ovarian can-
cers, the erbB-2 protein was found to be over-expressed 
frequently in urinary bladder carcinoma (Messing 1992; 
Sato et al 1992; Roberts and Der 2007) and it has also 
been found associated with increasing tumor grade, poor 
survival and incidence of metastatic disease (Moriyama 
et al 1991; Sato et al 1992; Gandour-Edwards et al 2002). 
The prognostic power of its over-expression increases when 
combined with other erbB receptors (especially EGFR 
and erbB-3) (Chow et al 2001). Of interest, in one study 
(Jimenez et al 2001) almost 70% of erbB-2 negative primary 
muscle-invasive tumors had erbB-2 positive corresponding 
distant metastasis.
From the bench to the bedside
Advances in the understanding of the molecular biology of 
UC continue to contribute to the identiﬁ  cation of molecular 
pathways upon which new therapeutic approaches can be 
designed. The goal of targeted therapy is to optimize the 
therapeutic ratio of an anti-neoplastic drug by maximizing 
its effect on tumor cells, and at the same time minimiz-
ing toxicity for normal cells. Various approaches have 
been developed to speciﬁ  cally targeting the phenotype of 
tumors. Such therapies involve the use of antibodies or 
small molecule enzyme inhibitors which interact with spe-
ciﬁ  cally target molecules differentially expressed between 
tumor and normal cells. In Table 2 the wide range of novel 
therapeutic agents (viral vector carrying wild-type genes, 
small molecule inhibitors and monoclonal antibodies) are 
summarized. Many of these agents are being introduced in 
clinical trials.
Table 2 Innovative targeted agents for metastatic bladder cancer treatment
Target  Agent  Mechanism of action
p53 mutated  AdCMV-TP53  Delivery of functional TP53 into cells (Pagliaro et al 2003b)
p53 mutated  rVV-TK-53  Delivery of functional TP53 into cells (Fodor et al 2005)
p53 mutated  ONYX-015  Delivery of functional TP53 into cells (Khuri et al 2000)
p53 wild-type and mutated  CP-31398  Restores mutant p53; stabilizes wild-type p53 (Ho and Li 2005;
    Tanner and Barberis 2004)
p53 mutated  PRIMA-1  Restores transcriptional activity of mutant p53 (Bykov et al 2005)
Rb-positive and negative cells  Ad-Rb94  Replaces Rb function (Zhang et al 2003)
Cyclin-dependent kinases  Flavopiridol  Nonspeciﬁ  c cyclin-dependent kinase inhibitor (Senderowicz 2003b)
Cyclin-dependent kinases  UCN-01  Nonspeciﬁ  c cyclin-dependent kinase inhibitor (Senderowicz 2003b)
EGFR Geﬁ  tinib  Inhibition of tyrosine kinase activity (Ciardiello et al 2000)
EGFR  Erlotinib  Inhibition of tyrosine kinase activity (Lindsey 2006; Meyerhardt et al 2006)
EGFR  Cetuximab  Prevents signal transduction (Inoue et al 2000)
erbB2  Trastuzumab  Inhibits HER2 and activates anti-tumor immune response (Hussain et al 2007; 
    Sawyers 2002; Small et al 2003)
Receptor tyrosine kinase  Sorafenib  Multikinase inhibitor (Carter et al 2007; Kupsch et al 2005; Panka et al 2006;
    Siu et al 2006)
VEGF  Endostatin  Inhibition of cell growth and migration (Kikuchi et al 2004)
VEGF  Bevacizumab  Binds  and inactivates VEGF (Jain et al 2006)
VEGF  VEGF Trap  Binds  and inactivates VEGF (Kim et al 2002)
VEGF  Sunitinib  Inhibition of tyrosine kinase activity (Silay and Miroglu 2007)
VEGF  Pazopanib  Inhibition of tyrosine kinase activity (ClinicalTrials.gov)
VEGF/EGFR  ZD6474  Inhibition of tyrosine kinase activity (Ciardiello et al 2003) 
Hypermethylated TSG promoters  5-Aza-CR  DNA incorporated (Mitra et al 2006)
Hypermethylated TSG promoters  5-Aza-CdR  DNA incorporated (Yoo and Jones 2006)
Topoisomerase I  Irinotecan  Topoisomerase I inhibition (ClinicalTrials.gov)
Histone deacetylase  Vorinostat  Histone deacetylase inhibitor (ClinicalTrials.gov)
20S proteasome  Bortezomib  dipeptidyl boronic acid inhibitor (Calabro and Sternberg 2006)Biologics: Targets & Therapy 2007:1(4) 400
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Targeting cell cycle regulators
The knowledge that genetic alterations of the TP53 gene 
occur in up to 70% of muscle-invasive bladder cancers 
(Knowles 2001) make TP53 gene an extremely attractive 
target for rationally designed therapies. Small molecules that 
can directly restore TP53 function are CP-31398 (Foster et al 
1999), which should restore the conformational structure and 
DNA-binding ability of mutant p53, and PRIMA-1 (P53 
Reactivation and Induction of Massive Apoptosis-1), which 
has been shown to suppress the growth of cells expressing 
mutant p53 (Bykov et al 2002) and to synergize with cisplati-
num to induce tumor cell apoptosis (Bykov et al 2005).
However, the most suitable approach to target p53 path-
way, seems to be the direct delivery of wild-type TP53 gene 
by viral vector in intra-vesical instillation. The ﬁ  rst clinical 
trial involving intra-vesical delivery of a gene therapy vector 
(vaccinia virus) has been published by our group (Gomella 
et al 2001). The vector used has been subsequently recom-
bined with TP53 (rVV-TK-53) in orthotopic murine animals 
(Fodor et al 2005). Similar gene therapy trials, in which 
adenovirus containing TP53 gene (AdCMV-TP53) was used, 
have demonstrated tumor inhibition in bladder cancer cell 
lines and xenograft models (Pagliaro, Keyhani, Liu et al 
2003). Two similar adenoviral vectors containing the TP53 
gene have been instilled into the bladder, both as single and 
multiple instillations, and have led to expression of functional 
p53 that can be detected in the bladder epithelium (Kuball 
et al 2002; Pagliaro, Keyhani, Liu et al 2003). In addiction, 
these trials involving intravesical instillation of the vector 
have revealed a high level of tolerance, increased transduc-
tion efﬁ  cacy and expression when used in combination with 
transduction-enhancing agents (Kuball et al 2002; Pagliaro, 
Keyhani, Liu et al 2003), and a synergistic effect in combi-
nation of cisplatin leading to increased apoptosis (Pagliaro, 
Keyhani, Williams et al 2003). Pagliaro, Keyhani, Williams 
et al (2003), observed evidence of tumor response in one of 
13 advanced superﬁ  cial bladder cancers treated.
Another gene therapy viral vector, which might be used 
in the delivery of a normal TP53 gene in bladder cancer 
cells, involves the selectively replicating adenovirus dl1520 
(ONYX-015) (Heise et al 1997). Deletion of the E1B 55 
kDa protein gene from the viral genome results in selective 
replication of cells that lack a functional p53 pathway. In 
normal cells with functional p53, the virus cannot replicate 
and is therefore harmless (Heise et al 1997; Ries and Korn 
2002). In a number of Phase I and Phase II clinical trials, 
the use of this viral vector has demonstrated a safety record 
and has been shown to be effective in combination with 
cisplatin, as combined-modality therapy (Khuri et al 2000). 
In a single study, treatment caused tumors to shrink in 25 
of the 30 cases evaluated (Khuri et al 2000). Objective 
responses (decrease of 50% or more) of injected tumors were 
documented in 63% of patients who could be evaluated (19 
of 30). There were 8 (27%) complete and 11 (36%) partial 
responses. ONYX-015 therefore represents an attractive 
agent for the treatment of the majority of high-risk TP53 
mutant bladder cancers. Similarly, conditionally replicating 
E1a-deleted adenoviruses (Hernandez-Alcoceba et al 2000)
may selectively target approximately 37% of muscle-
invasive bladder cancers which have shown mutations in 
the RB1 tumor suppressor gene. In normal bladder cells with 
functional Rb1, the absence of viral E1a gene function will 
prevent replication of the viral genome. However, in blad-
der tumors with mutant Rb1, there should be no effective 
barrier to viral replication and as with ONYX-015 in p53-
defective cells, the virus would be expected to be selectively 
apoptotic. Another vector carrying RB1 is Ad-RB94, which 
is a replication-deﬁ  cient adenoviral construct with Rb94, a 
protein which lacks 112 amino acid residues of the wild-type 
Rb1 protein (Rb110) resulting in a more potent tumor and 
growth suppressor than the normal protein (Xu et al 1994). 
This vector has been observed to be very selective to both 
bladder cancer RB1-negative and RB1-positive cells, induc-
ing growth suppression and caspase-dependent apoptosis 
(Zhang et al 2003).
Recent data proposed hyper-phosphorylation of RB1 as 
mechanism for Rb1 tumor suppressor pathway inactiva-
tion in bladder cancer (Chan et al 2002). Thus, a treatment 
leading to hypo-phosphorylation of the wild-type RB1 
promoter using CDKIs may improve prognosis. Recently, 
non-specific CDKIs like flavopiridol (L86-8275) and 
UCN-01 (7-hydroxystaurosporine) have entered clinical 
trials (Senderowicz 2003b). Moreover, ﬂ  avopiridol also 
decreases cyclin D1 levels, which are elevated in many UC 
cases (Senderowicz 2003a).
Targeting growth factor receptors
Two of the principal targets in the signal transduction cascade 
in metastatic and invasive tumors are EGFR and erbB-2 
proteins (Bellmunt, de Wit et al 2003; Bellmunt, Hussain 
et al 2003). A series of studies targeting both the EGFR and 
the erbB-2, which are overexpressed or ampliﬁ  ed in bladder 
cancer (Bue et al 1998; Gardmark et al 2005; Jimenez et al 
2001; Scholl et al 2001; Wester et al 2002), are under way 
and will help to deﬁ  ne the role of these new targeted therapies 
in the treatment of advanced UCs.Biologics: Targets & Therapy 2007:1(4) 401
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Several strategies have been designed to target these 
receptor tyrosine kinases (Mendelsohn 2000). The two 
most studied approaches to targeting EGFR are mono-
clonal antibodies against the extracellular domain of the 
receptor (Cetuximab/IMC-C225 [Erbitux]) and inhibi-
tors of the receptor tyrosine kinase domain (Geﬁ  tinib/
ZD1389 [Iressa], Erlotinib/OSI-774 [Tarceva]) (de Bono 
and Rowinsky 2002; Mendelsohn 2002). Trastuzumab 
(Herceptin), a monoclonal antibody against erbB-2, has 
prompted the initiation of a phase I/II clinical trial to 
determine the toxicity of combined chemo-radiotherapy 
(paclitaxel, carboplatin and gemcitabine) with or without 
this agent in patients with prior cystectomies for muscle 
invasive bladder cancer (ClinicalTrials.gov; Hussain et al 
2003; Calabro and Sternberg 2006; Hussain et al 2007). 
A recently introduced agent, sorafenib (BAY 43-9006 
[Nexavar]), is a multikinase inhibitor targeting various 
molecules, including EGFR and erbB-2, and is currently 
in phase II clinical trials for advanced and metastatic UC 
(ClinicalTrials.gov).
Based on the success seen with anti-erb-2 monoclonal 
antibodies and the promising results with EGFR targeted 
agents in other tumor types, there is a great interest in assess-
ing these agents in patients with bladder cancer. Inhibition 
of EGFR and erbB-2 pathways, either by physical receptor 
blockade or with small molecule inhibitors of the receptor’s 
tyrosine kinase activity, leads to demonstrable anti-tumor 
effects in animal models (Nicholson et al 2001; Mendelsohn 
2002; Hidalgo 2003). More importantly, multiple reports 
conﬁ  rm that EGFR directed therapy in combination with 
cytotoxics produces a much-enhanced biologic effect 
(Mendelsohn 2002). Blocking signaling through EGFR on 
tumor cell surfaces can promote apoptosis, inhibit angiogen-
esis and metastases, and consequently cause tumor regression 
(Izawa et al 2001).
Geﬁ  tinib, as erlotinib, inhibits the activity of tyrosine 
kinase in the intracellular component of the EGFR, thus 
preventing receptor autophosphorylation and subsequent 
activation (Slichenmyer and Fry 2001). The combination 
with platinum-derived agents (cisplatin, oxaliplatin, carbo-
platin), taxanes (paclitaxel, docetaxel) and topoisomerase 
inhibitors, shows enhanced growth inhibition (Ciardiello 
et al 2000). Its anti-proliferative effect in bladder cancers 
has been demonstrated in vitro and in vivo, and now it is 
in phase II clinical trials for advanced or metastatic UC 
(ClinicalTrials.gov; Dominguez-Escrig et al 2004; Nutt 
et al 2004). Erlotinib, in combination with green tea extract 
(Polyphenon E) is under study in a phase II clinical trial for 
preventing cancer recurrence in former smokers with resected 
UC (ClinicalTrials.gov).
Cetuximab binds to the EGFR with high afﬁ  nity, blocks 
ligand-induced tyrosine kinase activity and stimulates recep-
tor internalization. In vitro, proliferation of 253J B-V cells 
was inhibited more by the combination of cetuzimab and 
paclitaxel than with either cetuzimab or paclitaxel (Inoue 
et al 2000). The combination enhanced apoptosis in tumor 
and endothelial cells compared with either agent alone, most 
likely mediated by inhibition of angiogenesis and induc-
tion of apoptosis (Perrotte et al 1999). The combination of 
cetuximab and paclitaxel has been evaluated in mice with 
metastatic human bladder UC with encouraging results 
(Inoue et al 2000).
New therapeutic targets
One of the mechanisms used in cell transformation is the 
escape from the normal control mechanisms of the apoptotic 
process. In the attempt to predispose cancer cells to apoptosis, 
anti-sense oligonucleotide gene therapy directed to BCL-2 
mRNA has already been demonstrated to reverse cisplatin 
resistance in bladder tumor cell lines in vitro, (Hussain et al 
2003) and it will be interesting to see whether these results 
can be reproduced in pre-clinical models and in clinical 
trials.
Recently, the importance of VEGF and bFGF in advanced 
and metastatic UC has grown and a number of agents have 
been designed against them, many of which have already 
entered clinical trials. The most popular is endostatin, which 
decreases VEGF expression and tumor growth by inducing 
apoptosis (Du and Hou 2003). Moreover, the lentiviral gene 
transfer of endostatin by intravesical instillation decreases 
orthotopic human bladder tumor growth (Kikuchi et al 
2004). Bevacizumab (Avastin), a monoclonal antibody 
against VEGF, already used for other type of cancers (Jain 
et al 2006), is in phase II clinical trials in combination with 
cisplatin and gemcitabine for metastatic UC (ClinicalTrials.
gov). VEGF Trap consists in a fully humanized, soluble 
decoy VEGF receptor generated by fusing the extracellular 
domains of VEGFR-1 and VEGFR-2 to the Fc portion of 
human IgG1. The mechanism of action is very similar to 
bevacizumab, binding and inactivating VEGF. In preclini-
cal models it inhibits tumor growth and angiogenesis (Kim 
et al 2002). In addition, it is in use in clinical trials against 
metastatic UCs (ClinicalTrials.gov).
Bortezomib (PS-341) is a dipeptidyl boronic acid inhib-
itor of the 20S proteasome, which also inhibits secretion 
of the pro-angiogenic factors matrix metalloproteinase-9, Biologics: Targets & Therapy 2007:1(4) 402
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interleukin-8 (IL-8), and vascular endothelial growth 
factor (VEGF) (Zavrski et al 2005). The effects of bort-
ezomib on the growth of human 253JB-V bladder cancer 
cells showed inhibition of cell growth in a concentration-
dependent fashion and higher growth inhibitory effects of 
gemcitabine in vitro (Calabro and Sternberg 2006). These 
effects were associated with accumulation of p53 and p21 
and suppression of cyclin-dependent kinase 2 activity. In 
vivo studies with 253JB-V tumors growing in nude mice 
demonstrated that bortezomib did not inhibit tumor growth 
when it was delivered as a single agent. However, the 
combination therapy with bortezomib plus gemcitabine 
produced synergistic tumor growth inhibition associated 
with strong suppression of tumor cell proliferation (Calabro 
and Sternberg 2006).
The role of hyper-methylation of tumor suppressor gene 
promoters in UC has recently been stressed, highlighting 
the importance of using demethylating agents to reverse the 
hypermethylation in advanced and metastatic UCs (Cote 
et al 2005). The most used agents are nucleoside analogs 
such as 5-azacytidine (5-Aza-CR), 5-aza-2'-deoxycitidine 
(5-Aza-CdR, decitabine), and zebularine. These therapeutics 
have a modiﬁ  ed cytosine ring attached to either a ribose or 
deoxyribose moiety, which inhibits the DNA methylation 
(Yoo and Jones 2006) and they are now under study in the 
treatment of UC.
Apart from the herein mentioned therapeutic agents, other 
inhibitor classes such as anti-topoisomerase I (Irinotecan) 
and histone deacetylase inhibitors (vorinostat) are used at the 
moment in clinical trials for the treatment of advanced and 
metastatic UC (ClinicalTrials.gov), but further investigations 
are needed to clarify their role in bladder cancer treatment.
Conclusion
Although bladder cancer is one of the leading tumors in 
western world, very little is still known about the molecular 
mechanisms that determine tumor formation in the blad-
der urothelium and the process of its metastatization. A 
better understanding of the molecular biology of bladder 
cancer will undoubtedly inﬂ  uence the selection of new 
therapeutic modalities. The value of integrating new bio-
logically targeted agents into combined modality treatment 
for patients with metastatic bladder cancer has still to be 
proven. However, efﬁ  ciently designed and rationalized 
trials, targeting therapeutic approaches to the molecular 
and histological characteristics of urothelial cancers, hold 
promise to improve the current results of metastatic bladder 
cancer treatment.
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